MediFind
LoginSign Up
Are we missing a condition or feature you’d like to see? MediFind is always evolving and we’d love your feedback.
MediFind
Condition

Non-Alcoholic Fatty Liver Disease

Symptoms, Doctors, Treatments, Research & More

Active Clinical Trials

Clinical Trial
Behavioral
  • Status: Not yet recruiting
  • Study Type: Behavioral
  • Participants: 39
  • Start Date: July 1, 2021
A Gender and Culturally Specific Approach to Reduce NAFLD in Mexican-American Men
Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 1800
  • Start Date: April 2021
MMONARCh-1: Study of MSDC-0602K, a Modulator of the Mitochondrial Pyruvate Carrier for Outcomes in Patients With Pre Type 2 Diabetes (T2D) or T2D and NAFLD/NASH, Assessed for ImpRoved Glycemic Control and Cardiovascular Outcomes-1
Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 72
  • Start Date: March 2021
GULLIVER-1 - A Randomised, Double-Blind, Placebo Controlled, Phase Ib, 12-week Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered GB1211 in Participants With Suspected or Confirmed Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis
Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 270
  • Start Date: February 16, 2021
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (NASH)
Clinical Trial
Other
  • Status: Not yet recruiting
  • Participants: 1027
  • Start Date: January 2021
Diagnostic Accuracy of the LLIFT, a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome
Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 45
  • Start Date: January 1, 2021
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD): Relief-NAFLD
Clinical Trial
Dietary Supplement
  • Status: Not yet recruiting
  • Study Type: Dietary Supplement
  • Participants: 40
  • Start Date: January 1, 2021
Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic
Clinical Trial
Device
  • Status: Not yet recruiting
  • Study Type: Device
  • Participants: 150
  • Start Date: January 1, 2021
Assessment Of Non Alcoholic Fatty Liver Disease in Diabetic and Prediabetic Patients Using Non Invasive Methods
Clinical Trial
Diagnostic Test
  • Status: Not yet recruiting
  • Study Type: Diagnostic Test
  • Participants: 75
  • Start Date: January 1, 2021
Feasibility Study for Quantifying Fatty Liver Using Thermo-acoustic Imaging
Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 80
  • Start Date: December 30, 2020
Effect of Probiotics in Non-Alcoholic Fatty Liver Disease and Steatohepatitis Measured by Transient Elastography (PRONE Study).
Clinical Trial
Device
  • Status: Not yet recruiting
  • Study Type: Device
  • Participants: 533
  • Start Date: December 2020
Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Patients With Type 1 Diabetes Using Vibration-Controlled Transient Elastography and Noninvasive Scores
Clinical Trial
Drug
  • Status: Not yet recruiting
  • Study Type: Drug
  • Participants: 12
  • Start Date: December 1, 2020
A Prospective, Randomized, Placebo-Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Twice Weekly Administration of Lyophilized PRIM-DJ2727 or Placebo Given Orally for 12 Weeks in Subjects With Nonalcoholic Fatty Liver Disease (NAFLD)
Showing 1–12 of 403 Clinical Trials
Next